Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

Marzio E E Sabbioni, Monica Castiglione, Christoph Hürny, Hans Peter Siegrist, Marisa Bacchi, Jürg Bernhard, Beat Thürlimann, Hervé Bonnefoi, Lucien Perey, Aron Goldhirsch, Hans Jörg Senn

Research output: Contribution to journalArticlepeer-review

Abstract

The effects and interaction of endocrine and cytotoxic adjuvant treatment on measures of cellular immunity were assessed in 41 stage I-II breast cancer patients from International Breast Cancer Study Group trials. Counts of lymphocytes and lymphocyte subsets [(T, T4, T8, B, natural killer (NK) and activated T (AT) cells] were assessed by flow cytometry immediately before adjuvant therapy at baseline and on day 1 of the 3rd cycle. Twenty- two patients received cyclophosphamide, methotrexate and 5-fluorouracil (CMF), 7 CMF and tamoxifen (TAM), and 12 TAM alone. On day 1 of the 3rd cycle the counts of total lymphocytes (P=0.003) and all lymphocyte subsets (P

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalSupportive Care in Cancer
Volume7
Issue number3
DOIs
Publication statusPublished - May 1999

Keywords

  • Breast cancer
  • Cellular immunity
  • Cytotoxic treatment
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Fingerprint Dive into the research topics of 'Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients'. Together they form a unique fingerprint.

Cite this